Patents by Inventor Mette Gronborg
Mette Gronborg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9845344Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells. More specifically the invention relates to therapy based on the biological function of a secreted therapeutic protein, NsG33, in particular for the treatment of disorders of the nervous system. NsG33 is a nerve survival and growth factor with antiapoptotic effects on a cell line with neuronal potential and with neuroprotective and/or neurogenesis effects on a neural precursor cell line and on primary striatal cultures. The invention also relates to novel bioactive NsG33 polypeptide fragments and the corresponding encoding DNA sequences.Type: GrantFiled: March 30, 2005Date of Patent: December 19, 2017Assignee: HOBA THERAPEUTICS APSInventors: Mette Grønborg, Philip Kusk, Nikolaj Blom, Thomas Nordahl Petersen, Teit E. Johansen, Søren Brunak, Lars U. Wahlberg
-
Publication number: 20120184492Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells. More specifically the invention relates to therapy based on the biological function of a secreted therapeutic protein, NsG33, in particular for the treatment of disorders of the nervous system. NsG33 is a nerve survival and growth factor with antiapoptotic effects on a cell line with neuronal potential and with neuroprotective and/or neurogenesis effects on a neural precursor cell line and on primary striatal cultures. The invention also relates to novel bioactive NsG33 polypeptide fragments and the corresponding encoding DNA sequences.Type: ApplicationFiled: December 15, 2011Publication date: July 19, 2012Applicant: NsGene A/SInventors: Mette Grønborg, Philip Kusk, Nikolaj Blom, Thomas Nordahl Petersen, Teit E. Johansen, Soren Brunak, Lars U. Wahlberg
-
Patent number: 7601518Abstract: The present invention concerns improved methods and compositions for producing a Neublastin polypeptide as well as local delivery of Neublastin to specific regions of the nervous system including the central nervous system and the eye for example by gene therapy. The invention also concerns Neublastin expression constructs which do not encode a pro-region of a Neublastin polypeptide, which expression construct result in increased secretion of bioactive Neublastin. The invention includes the delivery of Neublastin from transduced or transfected cells encapsulated into a macrocapsule with a semipermeable membrane. The invention further concerns mammalian cells capable of producing Neublastin in increased amounts.Type: GrantFiled: June 10, 2004Date of Patent: October 13, 2009Assignee: NsGene A/SInventors: Lars U. Wahlberg, Mette Gronborg, Philip Kusk, Jens Tornoe
-
Patent number: 7595336Abstract: The present invention relates to novel isatin derivatives, pharmaceutical compositions comprising the isatin derivatives of the invention, methods of preparing the isatin derivatives of the invention, their use in the treatment of neurodegenerative diseases and for the regeneration or prevention of degeneration of lesioned and damaged neurons, and methods of treatment of neurodegenerative diseases and for the regeneration or prevention of degeneration of lesioned and damaged neurons.Type: GrantFiled: June 16, 2006Date of Patent: September 29, 2009Assignee: Neurosearch A/SInventors: Mette Gronborg, Dan Peters, Arne Moller
-
Publication number: 20090136552Abstract: Disclosed are NsG28, NsG30, NsG32 polypeptides, nucleic acids encoding NsG28, NsG30, NsG32 polypeptides, and antibodies that bind to NsG28, NsG30, NsG32 polypeptides as well as methods of making and using the same.Type: ApplicationFiled: August 1, 2005Publication date: May 28, 2009Inventors: Mette Gronborg, Philip Kusk, Nikolaj Blom, Thomas Nordahl Petersen, Teit E. Johansen, Soren Brunak, Lars U. Wahlberg
-
Publication number: 20090087474Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on secreted therapeutic proteins, NsG29 and NsG31. NsG29 and Ns31 are members of a newly identified family of growth factors with a specific cystein pattern and characterised by expression in the nervous system. The secreted growth factors have potential for the treatment of disorders of the nervous system. The invention also relates to bioactive NsG29 and NsG31 polypeptide fragments and the corresponding encoding DNA sequences.Type: ApplicationFiled: January 9, 2006Publication date: April 2, 2009Inventors: Thomas N. Petersen, Nikolaj Blom, Mette Gronborg, Philip Kusk, Soren Brunak, Teit E. Johansen, Lars U. Wahlberg
-
Publication number: 20080318853Abstract: The present invention relates to the field of diagnostic and therapeutic use of proteins and genes, in particular to the diagnostic and therapeutic use of a secreted human hormone/growth factor, Neublasmin, and use or the gene coding for Neublasmin in the diagnosis and treatment of testicular disorders, in particular diagnosis and treatment of germ cell tumours and infertility. The invention also relates to use of Neublasmin in the treatment of CNS disorders. Neublasmin is expressed at high levels in human adult testicles and in developing mouse testicles from pn 22 and onwards. Expression or Neublasmin is strongly up-regulated in carcinoma in situ. Expression is also seen in foetal and adult brain.Type: ApplicationFiled: November 4, 2005Publication date: December 25, 2008Applicant: NSGENE A/SInventors: Mette Gronborg, Nikolaj Blom
-
Publication number: 20070275026Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells. More specifically the invention relates to therapy based on the biological function of a secreted therapeutic protein. NsG33, in particular for the treatment of disorders of the nervous system. NsG33 is a nerve survival and growth factor with antiapoptotic effects on a cell line with neuronal potential and with neuroprotective and/or neurogenesis effects on a neural precursor cell line and on primary striatal cultures. The invention also relates to novel bioactive NsG33 polypeptide fragments and the corresponding encoding DNA sequences.Type: ApplicationFiled: March 30, 2005Publication date: November 29, 2007Applicant: NSGENE A/SInventors: Mette Gronborg, Philip Kusk, Nikolaj Blom, Thomas Petersen, Teit Johansen, Soren Brunak, Lars Wahlberg
-
Patent number: 7282511Abstract: The present invention relates to novel isatin derivatives, pharmaceutical compositions comprising the isatin derivatives of the invention, methods of preparing the isatin derivatives of the invention, their use in the treatment of neurodegenerative diseases and for the regeneration or prevention of degeneration of lesioned and damaged neurons, and methods of treatment of neurodegenerative diseases and for the regeneration or prevention of degeneration of lesioned and damaged neurons.Type: GrantFiled: January 23, 2001Date of Patent: October 16, 2007Assignee: Neurosearch A/SInventors: Mette Gronborg, Dan Peters, Arne Moller
-
Publication number: 20060229311Abstract: The present invention relates to novel isatin derivatives, pharmaceutical compositions comprising the isatin derivatives of the invention, methods of preparing the isatin derivatives of the invention, their use in the treatment of neurodegenerative diseases and for the regeneration or prevention of degeneration of lesioned and damaged neurons, and methods of treatment of neurodegenerative diseases and for the regeneration or prevention of degeneration of lesioned and damaged neurons.Type: ApplicationFiled: June 16, 2006Publication date: October 12, 2006Inventors: Mette Gronborg, Dan Peters, Arne Moller
-
Publication number: 20050089960Abstract: The present invention concerns improved methods and compositions for producing a Neublastin polypeptide as well as local delivery of Neublastin to specific regions of the nervous system including the central nervous system and the eye for example by gene therapy. The invention also concerns Neublastin expression constructs which do not encode a pro-region of a Neublastin polypeptide, which expression construct result in increased secretion of bioactive Neublastin. The invention includes the delivery of Neublastin from transduced or transfected cells encapsulated into a macrocapsule with a semipermeable membrane. The invention further concerns mammalian cells capable of producing Neublastin in increased amounts.Type: ApplicationFiled: June 10, 2004Publication date: April 28, 2005Applicant: NSGENE A/SInventors: Lars Wahlberg, Mette Gronborg, Philip Kusk, Jens Tornoe
-
Publication number: 20040247571Abstract: The invention provides a means for efficiently generating large numbers of TH expressing neural cells for neurotransplantation into a host to treat neurodegenerative disease, neurological trauma, stroke, or in other neurodegenerative disease, neurological trauma, stroke, or in other diseases of the nervous system involving loss of neural cells, particularly Parkinson's disease.Type: ApplicationFiled: May 26, 2004Publication date: December 9, 2004Inventors: Xia Meijer, Mette Gronborg, Lars Wahlberg
-
Publication number: 20040241170Abstract: The present invention relates to the use of antibodies recognising Fetal Antigen-1 (FA1/dlk1) for the detection and isolation of cell subpopulations from neural cell populations, in particular from cell populations from the central nervous system. In one embodiment, the dopaminergic neurons in the Substantia nigra pars compacta are detected and separated from other cell populations in this region of the brain. In another embodiment, neural stem and progenitor cells are isolated from other more committed cells in the CNS. The isolated cells may be used for transplantation, drug screening, production of cell type specific antibodies, and gene discovery.Type: ApplicationFiled: February 23, 2004Publication date: December 2, 2004Inventors: Charlotte Harken Jensen, Borge Teisner, Mette Gronborg, Lars U Wahlberg
-
Patent number: 6576641Abstract: The present invention relates to certain fused heterocyclic compounds (I) and their use in the treatment of neurodegenerative diseases and for the regeneration or prevention of degeneration of lesioned and damaged neurons.Type: GrantFiled: June 7, 2001Date of Patent: June 10, 2003Assignee: Neurosearch A/SInventors: Dan Peters, Mette Grønborg, Arne Møller
-
Publication number: 20030040518Abstract: The present invention relates to novel isatin derivatives, pharmaceutical compositions comprising the isatin derivatives of the invention, methods of preparing the isatin derivatives of the invention, their use in the treatment of neurodegenerative diseases and for the regeneration or prevention of degeneration of lesioned and damaged neurons, and methods of treatment of neurodegenerative diseases and for the regeneration or prevention of degeneration of lesioned and damaged neurons.Type: ApplicationFiled: July 1, 2002Publication date: February 27, 2003Inventors: Mette Gronborg, Dan Peters, Arne Moller
-
Publication number: 20020013336Abstract: 1Type: ApplicationFiled: June 7, 2001Publication date: January 31, 2002Inventors: Dan Peters, Mette Gronborg, Arne Moller